These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 31200821)

  • 1. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
    Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
    Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
    Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of KRAS
    Caballé-Perez E; Hernández-Pedro N; Ramos-Ramírez M; Barrios-Bernal P; Romero-Núñez E; Lucio-Lozada J; Ávila-Ríos S; Reyes-Terán G; Cardona AF; Arrieta O
    Clin Transl Oncol; 2024 Apr; 26(4):836-850. PubMed ID: 37490263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.